Ready-to-Use Vial Supply and Storage Requirements | Octagam 10%

Available in a range of convenient, ready-to-use vials, with a choice of filling sizes to meet individual needs

Octagam 10% liquid is supplied in 2 g, 5 g, 10 g, or 20 g single-use bottles

octagam_10 20ml 1g box vial

2.0 g (20 mL)

NDC Number
68982-850-01

octagam_10 50ml 5g box vial

5 g (50 mL)

NDC Number
68982-850-02

octagam_10 100ml 10g box vial

10 g (100 mL)

NDC Number
68982-850-03

octagam_10 200ml 20g box vial

20 g (200 mL)

NDC Number
68982-845-04

Storage

Octagam 10% liquid may be stored for 36 months at +2°C to +8°C (36°F to 46°F) from the date of manufacture

Within the first 12 months of this shelf-life, the product may be stored up to 9 months at ≤+25°C (77°F). After storage at ≤+25°C (77°F) the product must be used or discarded

Do not freeze. Do not use frozen product

Do not use after expiration date

Any unused product or waste material should be disposed of in accordance with local requirements

Octagam 10% liquid is not supplied with an infusion set

If a filtered infusion set is used (not mandatory), filter size must be 0.2 – 200 microns

Reference:

Octagam 10% Full Prescribing Information. Paramus, NJ: Octapharma; rev March 2022.

Indications and Important Safety Information for octagam^® Immune Globulin Intravenous (Human) 10% Liquid Preparation

WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE
Please see accompanying Full Prescribing Information for complete boxed warning and other important information.

Indications and Important Safety Information for octagam^® Immune Globulin Intravenous (Human) 10% Liquid Preparation

WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE
Please see accompanying Full Prescribing Information for complete boxed warning and other important information.

Thrombosis may occur with immune globulin intravenous (IgIV) products, including octagam 10%. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of Immune Globulin Intravenous (Human) (IgIV) products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IgIV products containing sucrose. Octagam 10% does not contain sucrose.
For patients at risk of thrombosis, renal dysfunction or renal failure, administer octagam 10% at the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Indications and Use

Octagam 10% is an immune globulin intravenous (human) liquid preparation indicated for the treatment of chronic immune thrombocytopenic purpura (ITP) in adults.

Important Safety Information

Contraindications
Octagam 10% is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin.

Octagam 10% contains trace amounts of lgA (average 106 μg/mL in a 10% solution). It is contraindicated in lgA–deficient patients with antibodies against lgA and history of hypersensitivity.

Warnings and Precautions
lgA-deficient patients with antibodies against lgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions to octagam 10%.
Epinephrine should be available immediately to treat any severe acute hypersensitivity reactions.

Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure.

Falsely elevated blood glucose readings may occur during and after the infusion of octagam 10% with testing by some glucometers and test strip systems.

Hyperproteinemia, increased serum osmolarity and hyponatremia may occur in patients receiving octagam 10%.

Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to octagam 10% treatments. Risk factors for hemolysis include high doses and non-0-blood group. Closely monitor patients for hemolysis and hemolytic anemia.

Aseptic meningitis syndrome may occur in patients receiving octagam 10%, especially with high doses or rapid infusion. Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI)).

Octagam 10% is made from human plasma and may contain infectious agents, e.g. viruses and, theoretically, the Creutzfeldt-Jakob disease agent.

Adverse Reactions
The most serious drug-related adverse event reported with octagam 10% treatment was a headache (0.9% of subjects). The most common drug- related adverse reactions reported in >5% of the subjects during a clinical trial were headache, fever, and increased heart rate.

Please see octagam 10%^® full Prescribing Information

FOR U.S. HEALTHCARE PROFESSIONALS ONLY

The information on this website has been specifically created for U.S. healthcare professionals (HCPs)